Skip to main navigation
UroGen Pharma
  • About Us
    • About Us
    • Management
    • Board of Directors
    • SAB and Clinical Advisors
  • Science
    • Science
    • Pipeline
      • Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
      • Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)
      • Carcinoma in Situ of the Bladder
      • Overactive Bladder
    • Grants
  • Partnerships
  • Investors
    • Investors
    • Press Releases
    • Events and Presentations
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • Stock Information
    • Investor FAQs
    • Information Request
    • Contact IR
  • Careers
  • Contact Us
  • Menu

Annual Reports

Annual Reports

2019 Proxy Statement
May 1, 2019
2019 Proxy Statement 296.5 KB
2018 Annual Report on Form 10-K
May 1, 2019
2018 Annual Report on Form 10-K 2 MB
  • Investors
  • Press Releases
  • Events and Presentations
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • SEC Filings
  • Annual Reports
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Investor FAQs
  • Information Request
  • Contact IR
  • Email Alerts
  • RSS Feeds
  • Print Page

Contact

UroGen Pharma
499 Park Avenue, Suite 1200
NY 10022, U.S.A
+1-646-768-9780 ext 1001

© Copyright | UroGen Pharma | Legal Disclaimer | Privacy Policy
    Scroll to top